Spectrum of cutaneous lesions in a cohort of patients with neurofibromatosis type 2
- 2 July 2024
- journal article
- research article
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (2) , 390-398
Abstract
Background: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant syndrome with a predisposition to the development of central nervous system tumors, ophthalmic manifestations, and dermatological lesions. The latter are present in 70–95% of patients and can precede the evolution of other tumors. However, they are not included in the diagnostic criteria and are frequently undervalued during follow‐up.Methods: An observational cross‐sectional study characterizing cutaneous lesions in a cohort of NF2 patients was carried out. Dermatological examinations were performed, and lesions were classified into neural cutaneous tumors (superficial, SNCT, and deep, DNCT), hyperpigmented patches (HyperP), and hypopigmented patches (HypoP). The Dermatology Life Quality Index (DLQI) and EQ‐5D questionnaires were applied to evaluate the impact on quality of life.Results: Nineteen patients with a mean age of 36 years were included. Sixteen (84%) patients had cutaneous lesions, mostly developed 10 or more years before the diagnosis. SNCT, DNCT, and HyperP showed similar frequencies (58%). HypoP were observed in only one patient. HyperP developed, on average, earlier than NCT (9.6 vs. 16.5 SNCT, 17.0 DNCT; years). The excised lesions had different histological patterns, including neurofibromas, schwannomas, and a hybrid tumor. Most patients reported a low impact of cutaneous manifestations on the quality of life (DLQI 0 or 1).Conclusions: Cutaneous lesions are frequent in NF2 and may precede the diagnosis by several years. Their identification is important to establish the diagnosis earlier and potentially reduce morbidity and mortality.Keywords
This publication has 18 references indexed in Scilit:
- Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendationGenetics in Medicine, 2022
- Hypopigmented macules in neurofibromatosis type 1: A case control studyJournal of the American Academy of Dermatology, 2021
- Presenting symptoms in children with neurofibromatosis type 2Child's Nervous System, 2020
- Café au Lait Macules and Associated Genetic SyndromesJournal of Pediatric Health Care, 2020
- Manifestaciones cutáneas de la neurofibromatosis tipo 2: interés diagnóstico y pronósticoActas Dermo-Sifiliograficas, 2017
- Neurofibromatosis type 2The Lancet, 2009
- Earliest Clinical Manifestations and Natural History of Neurofibromatosis Type 2 (NF2) in Childhood: A Study of 24 PatientsNeuropediatrics, 2005
- Skin Abnormalities in Neurofibromatosis 2Archives of Dermatology, 1997
- Prevalence of hypopigmented macules in a healthy populationThe Journal of Pediatrics, 1996
- Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneityAmerican Journal of Medical Genetics, 1994